CD28 and myeloid sarcoma: The results of this work show a reduction in the frequency of CD3-CD56+ PBMC (NK cells) expressing GM-CSF after blocking both IL-2 and IL-12 in PBMC from MS patients after anti-CD3/anti-CD28 stimulation but not in those from healthy controls.